Home › Funds › Soleus Capital Management, L.P. › EWTX

Soleus Capital Management, L.P. position in EWTX

EDGEWISE THERAPEUTICS INC · Health Care

Soleus Capital Management, L.P. reported holding 450,889 shares of EWTX (EDGEWISE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$18.3M, representing 0.63% of its reported portfolio and ranking #44 among its reported holdings. Soleus Capital Management, L.P. has disclosed EWTX holdings in 6 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)450.89K sh
Reported value held$18.32M
Portfolio Weight0.63%
First reportedQ4 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s EWTX position evolved

Soleus Capital Management, L.P. first disclosed a stake in EWTX in Q4 2024 at 183,300 shares (US$4.9M). The position peaked in Q1 2026 at 1,449,915 shares, worth US$45.7M. Across 6 filings, Soleus Capital Management, L.P. increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 450,889 shares valued at US$18.3M — a reduction of -999,026 shares quarter over quarter.. Notable position changes include a 61% trim in Q1 2025 (shares fell 40% over the following quarter), a 59% increase in Q1 2026 (shares rose 29% over the following quarter), a 69% trim in Q2 2026 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 183.30K $4.89M New
Q1 2025 72.30K $1.59M Reduce
Q2 2025 76.49K $1.00M Add
Q4 2025 910.00K $22.58M New
Q1 2026 1.45M $45.67M Add
Q2 2026 450.89K $18.32M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About EWTX and 13F data

EWTX (EDGEWISE THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in EWTX — the largest reported positions include ORBIMED ADVISORS LLC (US$630.5M), Paradigm Biocapital Advisors LP (US$415.1M), RA CAPITAL MANAGEMENT, L.P. (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding EWTX

All EWTX fund holders →

FAQ

How long has Soleus Capital Management, L.P. held EWTX?

Soleus Capital Management, L.P. has disclosed EWTX holdings in 6 of the last 7 reported quarters, going back to Q4 2024.

What is Soleus Capital Management, L.P.'s current position in EWTX?

As of Q2 2026, Soleus Capital Management, L.P. holds 450.89K shares of EWTX (EDGEWISE THERAPEUTICS INC), valued at $18.32M, representing 0.63% of its reported portfolio and ranking #44.

Has Soleus Capital Management, L.P. been buying or selling EWTX?

In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. reduced its position in EWTX. The position peaked in Q1 2026 at 1.45M shares.

Which other funds hold EWTX?

Other major institutional holders of EWTX include ORBIMED ADVISORS LLC, Paradigm Biocapital Advisors LP, RA CAPITAL MANAGEMENT, L.P., among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.